Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 9 | 64,052 | $1.02M |
| Grant or award | 7 | 133,000 | |
| Option exercise | 18 | 119,764 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
31 Form 4 filings on record, the earliest from Nov 20, 2024, newest first. Filing history page 1 of 2.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Carmine N. Stengone - Officer | Option exercise | Class A Common Stock | 2,500 | $1.01 | $3K | |
| Carmine N. Stengone - Officer | Open-market sale | Class A Common Stock | 2,500 | $16.01 | $40K | |
| Carmine N. Stengone - Officer | Option exercise | Stock Option (right to buy) | 2,500 | $0.00 | - | |
| Daniel S. Lorrain - Officer | Option exercise | Class A Common Stock | 1,015 | $1.01 | $1K | |
| Daniel S. Lorrain - Officer | Open-market sale | Class A Common Stock | 1,015 | $16.00 | $16K | |
| Daniel S. Lorrain - Officer | Option exercise | Class A Common Stock | 25 | $1.01 | $25 | |
| Daniel S. Lorrain - Officer | Open-market sale | Class A Common Stock | 25 | $16.00 | $400 | |
| Daniel S. Lorrain - Officer | Option exercise | Stock Option (right to buy) | 1,015 | $0.00 | - | |
| Daniel S. Lorrain - Officer | Option exercise | Stock Option (right to buy) | 25 | $0.00 | - | |
| Carmine N. Stengone - Officer | Option exercise | Class A Common Stock | 2,500 | $1.01 | $3K | |
| Carmine N. Stengone - Officer | Open-market sale | Class A Common Stock | 2,500 | $16.00 | $40K | |
| Carmine N. Stengone - Officer | Option exercise | Stock Option (right to buy) | 2,500 | $0.00 | - | |
| Daniel S. Lorrain - Officer | Open-market sale | Class A Common Stock | 5,852 | $15.67 | $92K | |
| Daniel S. Lorrain - Officer | Open-market sale | Class A Common Stock | 2,501 | $16.24 | $41K | |
| Daniel S. Lorrain - Officer | Option exercise | Stock Option (right to buy) | 28,826 | $0.00 | - | |
| Daniel S. Lorrain - Officer | Option exercise | Stock Option (right to buy) | 4,183 | $0.00 | - | |
| Daniel S. Lorrain - Officer | Option exercise | Class A Common Stock | 28,826 | $1.01 | $29K | |
| Daniel S. Lorrain - Officer | Open-market sale | Class A Common Stock | 28,826 | $16.04 | $462K | |
| Daniel S. Lorrain - Officer | Option exercise | Class A Common Stock | 4,183 | $1.01 | $4K | |
| Option exercise | Class A Common Stock | 10,833 | $4.50 | $49K | ||
| Open-market sale | Class A Common Stock | 10,833 | $16.02 | $174K | ||
| Option exercise | Stock Option (right to buy) | 10,833 | $0.00 | - | ||
| Carmine N. Stengone - Officer | Option exercise | Class A Common Stock | 7,500 | $1.01 | $8K | |
| Carmine N. Stengone - Officer | Option exercise | Class A Common Stock | 2,500 | $1.26 | $3K | |
| Carmine N. Stengone - Officer | Open-market sale | Class A Common Stock | 10,000 | $16.01 | $160K | |
| Carmine N. Stengone - Officer | Option exercise | Stock Option (right to buy) | 7,500 | $0.00 | - | |
| Carmine N. Stengone - Officer | Option exercise | Stock Option (right to buy) | 2,500 | $0.00 | - | |
| Gines Diego Miralles - Director | Grant or award | Stock Option (right to buy) | 19,000 | $0.00 | - | |
| Lori Lyons-Williams - Director | Grant or award | Stock Option (right to buy) | 19,000 | $0.00 | - | |
| Olivia C. Ware - Director | Grant or award | Stock Option (right to buy) | 19,000 | $0.00 | - | |
| Evert B. Schimmelpennink - Director | Grant or award | Stock Option (right to buy) | 19,000 | $0.00 | - | |
| Grant or award | Stock Option (right to buy) | 19,000 | $0.00 | - | ||
| Todd R. Brady - Director | Grant or award | Stock Option (right to buy) | 19,000 | $0.00 | - | |
| Sarah Boyce - Director | Grant or award | Stock Option (right to buy) | 19,000 | $0.00 | - | |
| Daniel S. Lorrain - Officer | Open-market sale | Class A Common Stock | 4,170 | $13.16 | $55K | |
| Daniel S. Lorrain - Officer | Open-market sale | Class A Common Stock | 3,870 | $13.06 | $51K | |
| Daniel S. Lorrain - Officer | Open-market sale | Class A Common Stock | 300 | $13.84 | $4K | |
| Daniel S. Lorrain - Officer | Open-market sale | Class A Common Stock | 4,170 | $13.43 | $56K | |
| Daniel S. Lorrain - Officer | Open-market sale | Class A Common Stock | 4,170 | $15.01 | $63K | |
| Option exercise | Class A Common Stock | 3,611 | $4.50 | $16K | ||
| Open-market sale | Class A Common Stock | 3,611 | $15.02 | $54K | ||
| Option exercise | Stock Option (right to buy) | 3,611 | $0.00 | - | ||
| Carmine N. Stengone - Officer | Option exercise | Class A Common Stock | 4,400 | $1.26 | $6K | |
| Carmine N. Stengone - Officer | Open-market sale | Class A Common Stock | 4,400 | $16.02 | $70K | |
| Carmine N. Stengone - Officer | Option exercise | Class A Common Stock | 2,700 | $1.26 | $3K | |
| Carmine N. Stengone - Officer | Open-market sale | Class A Common Stock | 2,700 | $16.02 | $43K | |
| Carmine N. Stengone - Officer | Option exercise | Stock Option (right to buy) | 4,400 | $0.00 | - | |
| Carmine N. Stengone - Officer | Option exercise | Stock Option (right to buy) | 2,700 | $0.00 | - | |
| Daniel S. Lorrain - Officer | Option exercise | Class A Common Stock | 4,300 | $1.01 | $4K | |
| Daniel S. Lorrain - Officer | Open-market sale | Class A Common Stock | 4,300 | $16.03 | $69K | |
| Daniel S. Lorrain - Officer | Option exercise | Stock Option (right to buy) | 4,300 | $0.00 | - | |
| Daniel S. Lorrain - Officer | Option exercise | Class A Common Stock | 3,824 | $1.01 | $4K | |
| Daniel S. Lorrain - Officer | Open-market sale | Class A Common Stock | 3,824 | $16.01 | $61K | |
| Daniel S. Lorrain - Officer | Option exercise | Stock Option (right to buy) | 3,824 | $0.00 | - | |
| Daniel S. Lorrain - Officer | Option exercise | Class A Common Stock | 100 | $1.01 | $101 | |
| Daniel S. Lorrain - Officer | Open-market sale | Class A Common Stock | 100 | $16.00 | $2K | |
| Daniel S. Lorrain - Officer | Option exercise | Stock Option (right to buy) | 100 | $0.00 | - | |
| Carmine N. Stengone - Officer | Option exercise | Class A Common Stock | 400 | $1.26 | $504 | |
| Carmine N. Stengone - Officer | Open-market sale | Class A Common Stock | 400 | $16.00 | $6K | |
| Carmine N. Stengone - Officer | Option exercise | Stock Option (right to buy) | 400 | $0.00 | - | |
| Daniel S. Lorrain - Officer | Option exercise | Class A Common Stock | 400 | $1.01 | $404 | |
| Daniel S. Lorrain - Officer | Open-market sale | Class A Common Stock | 400 | $16.00 | $6K | |
| Daniel S. Lorrain - Officer | Option exercise | Stock Option (right to buy) | 400 | $0.00 | - | |
| Daniel S. Lorrain - Officer | Open-market sale | Class A Common Stock | 3,000 | $14.82 | $44K | |
| Daniel S. Lorrain - Officer | Open-market sale | Class A Common Stock | 1,170 | $15.25 | $18K | |
| John Stephen Healy - Officer | Grant or award | Stock Option (right to buy) | 206,411 | $0.00 | - | |
| Peter T. Slover - Officer | Grant or award | Stock Option (right to buy) | 192,000 | $0.00 | - | |
| Carmine N. Stengone - Officer | Grant or award | Stock Option (right to buy) | 445,000 | $0.00 | - | |
| Daniel S. Lorrain - Officer | Grant or award | Stock Option (right to buy) | 160,000 | $0.00 | - | |
| Daniel S. Lorrain - Officer | Grant or award | Stock Option (right to buy) | 6,500 | $0.00 | - | |
| Option exercise | Class A Common Stock | 3,611 | $4.50 | $16K | ||
| Open-market sale | Class A Common Stock | 2,800 | $14.09 | $39K | ||
| Open-market sale | Class A Common Stock | 811 | $14.48 | $12K | ||
| Option exercise | Stock Option (right to buy) | 3,611 | $0.00 | - | ||
| Grant or award | Stock Option (right to buy) | 160,000 | $0.00 | - | ||
| Daniel S. Lorrain - Officer | Open-market sale | Class A Common Stock | 1,010 | $16.02 | $16K |
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Daniel Lorrain | Officer | 9,520 | $147K | View on EDGAR | |
| CARMINE STENGONE | Director | 2,500 | $39K | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Contineum Therapeutics, Inc. (CTNM) had 13 insider filings in the last 90 days, with the most recent on 2026-08-03. The full record for CTNM runs to 31 Form 4 filings, the earliest from 2024-11-20. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of CTNM were filed in the last 90 days.
9 insider sales of CTNM were filed in the last 90 days, totaling $1.02M.
This page tracks CTNM Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add CTNM to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.